hrp0082p2-d2-333 | Diabetes (1) | ESPE2014

A Novel AVPR2 Mutation (L161P) Causing Partial Nephrogenic Diabetes Insipidus

Yamashita Sumie , Hata Astuko , Kaneko Naoto , Usui Takeshi , Hata Daisuke

Background: Nephrogenic diabetes insipidus (NDI) is a disorder characterized by renal resistance to the antidiuretic effect of AVP. Affected patients are exhibiting symptoms as polyuria and polydipsia. Approximately 90% of congenital NDI are inherited in an X-linked recessive manner and caused by mutations of arginine vasopressin type 2 receptor (AVPR2) gene.Objective and hypotheses: An 8-year-old Japanese boy was referred to our hospital for nocturnal e...

hrp0095p1-425 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Association between mothers, breast milk, and infants vitamin D at 2 weeks of age in Japan.

Yatsuga Shuichi , Saiki Reo , Eshima Nobuoki , Kitamura Miyuki , Ebina Masayuki , Takamura Takumi , Motogi Kazutaka , Inoue Yoshiyuki , Umino Satoko , Mukasa Rio , Goto Maki , Yokomine Masato , Yamashita Yushiro

Introduction: Breast milk is a perfect food, but it can be deficient in vitamin D. In the Danish study, vitamin D was correlated in mothers, breast milk and not in breast milk and infants. We investigated the correlation between mother, breast milk, and infants vitamin D levels in Japan.Materials and Methods: This study included 84 pairs of mothers and 2-week-old infants born at the Iizuka Hospital and Vitamin D includin...

hrp0089fc11.3 | Bone, Growth Plate & Mineral Metabolism 2 | ESPE2018

Evidence for Effects of FGF2 Aptamer in an Achondroplasia Mice Model and an In Vitro Chondrocyte Differentiation System Using Patient-Derived iPS Cells

Ozono Keiichi , Yasuda Kie , Kimura Takeshi , Nakano Yukako , Kitabatake Yasuji , Kubota Takuo , Nonaka Yosuke , Fujiwara Masatoshi , Nakamura Yoshikazu

Achondroplasia (Ach) is a skeletal disorder caused by gain-of-function mutations of FGFR3. Ach patients suffer from various complications such as short stature, foramen magnum stenosis and sleep apnea. Disease-specific treatment is not available at present, although some drugs including a C-type natriuretic peptide analogue have been developed. The mutated FGFR3, G380R, has an elevated activity of the receptor-associated tyrosine kinase, but G380R is further activated...